Republicans Favor Regulatory ‘Leeway’ On Drug Use During Emergencies, Bright Hearing Shows
In a Congressional hearing reminiscent of the right-to-try law debates, Democrats praised ousted BARDA Director Rick Bright for whistleblowing on the political interference in COVID-19 drug decisions, while Republicans argued the government should lower its standards during a pandemic and permit more widespread use of experimental medicines prior to clinical data.
You may also be interested in...
In whistleblower complaint, Rick Bright claims FDA Commissioner Hahn advocated for distributing hydroxychloroquine to pharmacies across the US, a departure from the approved emergency use authorization. Bright's complaint paints CDER Director Woodcock in a favorable light, saying she helped avoid an expanded access IND protocol for the potential coronavirus treatment.
As potentially life-threatening heart problems emerge in coronavirus patients, FDA says hydroxychloroquine should be taken only in clinical trial or hospital settings under the Emergency Use Authorization.
Rick Bright is requesting an inspector general investigation into his removal as director of the Biomedical Advanced Research and Development, accusing the Trump administration of favoring politics over science when making COVID-19 funding decisions.